Skip to content
  • Home
  • About
  • Contact
  • Services
  • Advertise with Us
US Pharma Marketing Logo

US Pharma Marketing

  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A

Strategy & Execution

How-tos, frameworks, omnichannel planning, and marketing roadmaps.

Why Early Market Research Can Prevent Clinical Trial Failure in the U.S. Pharmaceutical Industry
Posted in
  • Strategy & Execution

Why Early Market Research Can Prevent Clinical Trial Failure in the U.S. Pharmaceutical Industry

Clinical trial failure remains one of the most expensive risks in pharmaceutical development. Drug companies invest … Why Early Market Research Can Prevent Clinical Trial Failure in the U.S. Pharmaceutical IndustryRead more

by Jayshree Gondane•March 5, 2026March 5, 2026•0
Why Pharma Needs a Patient-Centric Sales Model
Posted in
  • Strategy & Execution

Why Pharma Needs a Patient-Centric Sales Model

For decades, pharmaceutical sales strategies focused primarily on physicians. Sales representatives built relationships with doctors, presented … Why Pharma Needs a Patient-Centric Sales ModelRead more

by Jayshree Gondane•March 5, 2026March 5, 2026•0
Why Physician Education Drives Faster Drug Adoption
Posted in
  • Strategy & Execution

Why Physician Education Drives Faster Drug Adoption

The success of a new pharmaceutical product does not depend solely on regulatory approval or clinical … Why Physician Education Drives Faster Drug AdoptionRead more

by Jayshree Gondane•March 5, 2026March 5, 2026•0
How Poor Forecasting Impacts U.S. Drug Commercialization
Posted in
  • Strategy & Execution

How Poor Forecasting Impacts U.S. Drug Commercialization

U.S. prescription drug spending reached nearly $722 billion in 2023, according to CMS data available at https://data.cms.gov. … How Poor Forecasting Impacts U.S. Drug CommercializationRead more

by Jayshree Gondane•March 4, 2026March 4, 2026•0
Why Many Pharma Launches Miss Revenue Targets in the U.S. Market
Posted in
  • Case Studies & Trends
  • Strategy & Execution

Why Many Pharma Launches Miss Revenue Targets in the U.S. Market

Roughly half of new drug launches in the United States fail to meet first-year revenue expectations. … Why Many Pharma Launches Miss Revenue Targets in the U.S. MarketRead more

by Jayshree Gondane•March 1, 2026March 1, 2026•0
Why Pharma Companies Overinvest in Sales and Underinvest in Strategy
Posted in
  • Strategy & Execution

Why Pharma Companies Overinvest in Sales and Underinvest in Strategy

In the U.S. pharmaceutical industry, companies often allocate disproportionately high budgets to sales forces while underinvesting … Why Pharma Companies Overinvest in Sales and Underinvest in StrategyRead more

by Jayshree Gondane•February 27, 2026February 27, 2026•0
Top 7 Go-To-Market Mistakes in Pharma Launches
Posted in
  • Strategy & Execution

Top 7 Go-To-Market Mistakes in Pharma Launches

Bringing a drug to market is often described as one of the most complex and capital-intensive … Top 7 Go-To-Market Mistakes in Pharma LaunchesRead more

by Jayshree Gondane•February 27, 2026February 27, 2026•0
How Sales and Marketing Misalignment Slows Revenue Growth
Posted in
  • Strategy & Execution

How Sales and Marketing Misalignment Slows Revenue Growth

In the pharmaceutical industry, sales and marketing teams are critical drivers of revenue growth, yet misalignment … How Sales and Marketing Misalignment Slows Revenue GrowthRead more

by Jayshree Gondane•February 26, 2026February 26, 2026•0
Why Pharma Marketing Needs to Be Education-First
Posted in
  • Strategy & Execution
  • Uncategorized

Why Pharma Marketing Needs to Be Education-First

In today’s healthcare landscape, traditional marketing tactics focused solely on promotion no longer suffice. Patients, healthcare … Why Pharma Marketing Needs to Be Education-FirstRead more

by Jayshree Gondane•February 26, 2026February 26, 2026•0
Why Pharma Companies Lose Momentum After Drug Approval
Posted in
  • Strategy & Execution

Why Pharma Companies Lose Momentum After Drug Approval

In the United States pharmaceutical industry, receiving approval from the U.S. Food and Drug Administration is widely regarded … Why Pharma Companies Lose Momentum After Drug ApprovalRead more

by Jayshree Gondane•February 25, 2026February 25, 2026•0

Posts pagination

Previous 1 2 3 4 … 21 Next

Recent Posts

  • Voice AI in Pharma Patient Engagement: How Smart Speakers Are Changing Adherence, Access, and the Next Front Door of Healthcare
  • How AI Is Automating Pharma Content Supply Chains and Rewiring the Economics of Medical, Legal, and Commercial Content
  • Predictive Analytics for Pharma Product Launch Forecasting: The Commercial Intelligence System Deciding Which Drug Launches Win
  • AI for Real-World Evidence in Pharma Marketing: How Commercial Teams Turn Clinical Data Into Market Access, Physician Trust, and Revenue Growth
  • Digital Twins in Pharmaceutical Manufacturing and Marketing: How Real-Time Simulation Is Redefining Drug Production, Commercial Strategy, and Market Advantage

Recent Comments

No comments to show.
Copyright © 2026 US Pharma Marketing.
Powered by WordPress and HybridMag.
  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A